

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Examiner:

Jennifer K. Michener

Michal et al.

Serial No.

09/918,365

Art Unit:

1762

Filed:

July 30, 2001

Title:

COVALENTLY IMMOBILIZED HEPARIN INTO AND ONTO

FUNCTIONALIZED POLYURETHANE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §\$1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. Since an identical Form 1449 was previously submitted on September 22, 2005 along with copies of the cited references, Applicants have not provided an additional copy of the cited references.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed with a Request for Continued Examination and before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: November 15, 2005

SQUIRE, SANDERS & DEMPSEY L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Facsimile (415) 393-9887 Respectfully submitted,

Mark Lupkowski/Ph.D. Attorney for Applicants

Reg. No. 49,010

FORM PTO-1449 (Modified)
-----------------	-----------

US DEPARTMENT OF COMMERCE Doo

US Patent and Trademark Office

cket No.	Application No.
50623.379	09/918,365

Michal et al.

ON Applicant

09/9/10,50

Filing Date
July 30, 2001

Group Art Unit 1762

NOV 1 5 2005

INFORMATION DISCLOSURE CITATION
in an Application
(Use several sheets if necessary)

TAHOEMAR	LOFFE .	U.S. PATENT DOCUMENTS						
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate	
	A1	2,072,303	3/2/37	Herrmann et al.				
	A2	2,386,454	10/9/45	Frosch et al.				
	А3	3,773,737	11/20/73	Goodman et al.				
_	A4	3,849,514	11/19/74	Gray, Jr. et al.				
····	A5	4,226,243	10/7/80	Shalaby et al.				
	A6	4,329,383	5/11/82	Joh				
	A7	4,343,931	8/10/82	Barrows				
	A8	4,529,792	7/16/85	Barrows				
	A9	4,611,051	9/9/86	Hayes et al.				
	A10	4,656,242	4/7/87	Swan et al.				
	A11	4,733,665	3/29/88	Palmaz				
	A12	4,800,882	1/31/89	Gianturco				
:	A13	4,882,168	11/21/89	Casey et al.				
	A14	4,886,062	12/12/89	Wiktor				
•	A15	4,931,287	6/5/90	Bae et al.				
	A16	4,941,870	7/17/90	Okada et al.				
•	A17	4,977,901	12/18/90	Ofstead				
	A18	5,019,096	5/28/91	Fox, Jr. et al.				
	A19	5,100,992	3/31/92	Cohn et al.				
	A20	5,112,457	5/12/92	Marchant				
	A21	5,133,742	7/28/92	Pinchuk				
	A22	5,163,952	11/17/92	Froix				
	A23	5,165,919	11/24/92	Sasaki et al.				
	A24	5,219,980	6/15/93	Swidler				
	A25	5,258,020	11/2/93	Froix				

	A26	5,272,012	12/21/93	Opolski		
	A27	5,292,516	3/8/94	Viegas et al.		
	A28	5,298,260	3/29/94	Viegas et al.		
	A29	5,300,295	4/5/94	Viegas et al.		
	A30	5,306,501	4/26/94	Viegas et al.		
	A31	5,306,786	4/26/94	Moens et al.		
	A32	5,328,471	7/12/94	Slepian		
	A33	5,330,768	7/19/94	Park et al.		
	A34	5,380,299	1/10/95	Fearnot et al.		
	A35	5,417,981	5/23/95	Endo et al.		
	A36	5,447,724	9/5/95	Helmus et al.		
	A37	5,455,040	10/3/95	Marchant		
	A38	5,462,990	10/31/95	Hubbell et al.		
	A39	5,464,650	11/7/95	Berg et al.		
	A40	5,485,496	1/16/96	Lee et al.		
	A41	5,516,881	5/14/96	Lee et al.		
	A42	5,569,463	10/29/96	Helmus et al.		
	A43	5,578,073	11/26/96	Haimovich et al.		
	A44	5,584,877	12/17/96	Miyake et al.		
	A45	5,605,696	2/25/97	Eury et al.		
	A46	5,607,467	3/4/97	Froix		,
	A47	5,609,629	3/11/97	Fearnot et al.		
,	A48	5,610,241	3/11/97	Lee et al.		
	A49	5,616,338	4/1/97	Fox, Jr. et al.		
	A50	5,624,411	4/29/97	Tuch		
	A51	5,628,730	5/13/97	Shapland et al.		
	A52	5,644,020	7/1/97	Timmermann et al.		
	A53	5,649,977	7/22/97	Campbell		
	A54	5,658,995	8/19/97	Kohn et al.		
	A55	5,667,767	9/16/97	Greff et al.		
	A56	5,670,558	9/23/97	Onishi et al.		
	A57	5,674,242	10/7/97	Phan et al.		

	A58	5,679,400	10/21/97	Tuch		
	A59	5,700,286	12/23/97	Tartaglia et al.		
	A60	5,702,754	12/30/97	Zhong		
	A61	5,711,958	1/27/98	Cohn et al.		
	A62	5,716,981	2/10/98	Hunter et al.		
	A63	5,721,131	2/24/98	Rudolph et al.		
•	A64	5,723,219	3/3/98	Kolluri et al.		
	A65	5,735,897	4/7/98	Buirge		
	A66	5,746,998	5/5/98	Torchilin et al.	Ť	
	A67	5,759,205	6/2/98	Valentini		· · · · · · · · · · · · · · · · · · ·
	A68	5,776,184	7/7/98	Tuch		
	A69	5,783,657	7/21/98	Pavlin et al.		
	A70	5,788,979	8/4/98	Alt et al.		
) 	A71	5,800,392	9/1/98	Racchini		
	A72	5,820,917	10/13/98	Tuch		
	A73	5,824,048	10/20/98	Tuch		
	A74	5,824,049	10/20/98	Ragheb et al.		
	A75	5,830,178	11/3/98	Jones et al.		
	A76	5,837,008	11/17/98	Berg et al.		
	A77	5,837,313	11/17/98	Ding et al.		
	A78	5,849,859	12/15/98	Acemoglu		
	A79	5,851,508	12/22/98	Greff et al.		
	A80	5,854,376	12/29/98	Higashi		
•	A81	5,857,998	1/12/99	Barry		
	A82	5,858,746	1/12/99	Hubbell et al.	1	
	A83	5,865,814	2/2/99	Tuch		·
	A84	5,869,127	2/9/99	Zhong		
	A85	5,873,904	2/23/99	Ragheb et al.		····
	A86	5,876,433	3/2/99	Lunn		
	A87	5,877,224	3/2/99	Brocchini et al.		
	A88	5,879,713	3/9/99	Roth et al.		
	A89	5,902,875	5/11/99	Roby et al.		

•	A90	5,905,168	5/18/99	Dos Santos et al.		
-	A91	5,910,564	6/8/99	Gruning et al.		
	A92	5,914,387	6/22/99	Roby et al.		
	A93	5,919,893	7/6/99	Roby et al.		
	A94	5,925,720	7/20/99	Kataoka et al.		
	A95	5,932,299	8/3/99	Katoot		
•	A96	5,955,509	9/21/99	Webber et al.		
	A97	5,958,385	9/28/99	Tondeur et al.		
	A98	5,962,138	10/5/99	Kolluri et al.		
	A99	5,971,954	10/26/99	Conway et al.		
	A100	5,980,928	11/9/99	Terry		
	A101	5,980,972	11/9/99	Ding	·	
	A102	5,997,517	12/7/99	Whitbourne		
	A103	6,010,530	1/4/00	Goicoechea		<u>.</u>
-	A104	6,011,125	1/4/00	Lohmeijer et al.		
	A105	6,015,541	1/18/00	Greff et al.		
	A106	6,033,582	3/7/00	Lee et al.		·
	A107	6,034,204	3/7/00	Mohr et al.		
	A108	6,042,875	3/28/00	Ding et al.		
	A109	6,051,648	4/18/00	Ashton et al.		
	A110	6,051,648	4/18/00	Rhee et al.		
	A111	6,054,553	4/25/00	Groth et al.		
	A112	6,056,993	5/2/00	Leidner et al.		
•	A113	6,060,451	5/9/00	DiMaio et al.		
	A114	6,060,518	5/9/00	Kabanov et al.		
	A115	6,080,488	6/27/00	Hostettler et al.		
	A116	6,096,070	8/1/00	Ragheb et al.		
	A117	6,099,562	8/8/00	Ding et al.		. , ,
	A118	6,110,188	8/29/00	Narciso, Jr.		
	A119	6,110,483	8/29/00	Whitbourne et al.		
	A120	6,113,629	9/5/00	Ken		
	A121	6,120,491	9/19/00	Kohn et al.		

							
	A122	6,120,536	9/19/00	Ding et al.			
	A123	6,120,788	9/19/00	Barrows			
-	A124	6,120,904	9/19/00	Hostettler et al.			
	A125	6,121,027	9/19/00	Clapper et al.			
	A126	6,129,761	10/10/00	Hubbell			
	A127	6,136,333	10/24/00	Cohn et al.		i	
	A128	6,143,354	11/7/00	Koulik et al.			
	A129	6,153,252	11/28/00	Hossainy et al.			
	A130	6,159,978	12/12/00	Myers et al.			
	A131	6,165,212	12/26/00	Dereume et al.			
	A132	6,172,167	1/9/01	Stapert et al.			
	A133	6,177,523	1/23/01	Reich et al.			
	A134	6,180,632	1/30/01	Myers et al.			
	A135	6,203,551	3/20/01	Wu			
	A136	6,211,249	4/3/01	Cohn et al.			
	A137	6,214,901	4/10/01	Chudzik et al.			
•	A138	6,231,600	5/15/01	Zhong			
	A139	6,240,616	6/5/01	Yan			
	A140	6,245,753	6/12/01	Byun et al.			
	A141	6,245,760	6/12/01	He et al.			
	A142	6,248,129	6/19/01	Froix			
	A143	6,251,136	6/26/01	Guruwaiya et al.			
	A144	6,254,632	7/3/01	Wu et al.			
	A145	6,258,121	7/10/01	Yang et al.			
	A146	6,258,371	7/10/01	Koulik et al.			
	A147	6,262,034	7/17/01	Mathiowitz et al.			
	A148	6,270,788	8/7/01	Koulik et al.			
,	A149	6,277,449	8/21/01	Kolluri et al.			
	A150	6,283,947	9/4/01	Mirzaee			
	A151	6,283,949	9/4/01	Roorda			
·····	A152	6,284,305	9/4/01	Ding et al.			

A153	6,287,628	9/11/01	Hossainy et al.	
A154	6,299,604	10/9/01	Ragheb et al.	
A155	6,306,176	10/23/01	Whitbourne	
A156	6,331,313	12/18/01	Wong et al.	
A157	6,335,029	1/1/02	Kamath et al.	
A158	6,344,035	2/5/02	Chudzik et al.	
A159	6,346,110	2/12/02	Wu	
A160	6,358,556	3/19/02	Ding et al.	
A161	6,379,381	4/30/02	Hossainy et al.	
A162	6,387,379	5/14/02	Goldberg et al.	
A163	6,395,326	5/28/02	Castro et al.	
A164	6,419,692	7/16/02	Yang et al.	
A165	6,451,373	9/17/02	Hossainy et al.	
A166	6,482,834	11/19/02	Spada et al.	
A167	6,494,862	12/17/02	Ray et al.	
A168	6,503,538	1/7/03	Chu et al.	
A169	6,503,556	1/7/03	Harish et al.	·
A170	6,503,954	1/7/03	Bhat et al.	,
A171	6,506,437	1/14/03	Harish et al.	
A172	6,524,347	2/25/03	Myers et al.	
A173	6,527,801	3/4/03	Dutta	
A174	6,527,863	3/4/03	Pacetti et al.	
- A175	6,528,526	3/4/03	Myers et al.	
A176	6,530,950	3/11/03	Alvarado et al.	
A177	6,530,951	3/11/03	Bates et al.	
A178	6,540,776	4/1/03	Sanders Millare et al.	
A179	6,544,223	4/8/03	Kokish	
A180	6,544,543	4/8/03	Mandrusov et al.	
A181	6,544,582	4/8/03	Yoe	
A182	6,555,157	4/29/03	Hossainy	
A183	6,558,733	5/6/03	Hossainy et al.	

	A184	6,565,659	5/20/03	Pacetti et al.	6/28/01
	A185	6,572,644	6/3/03	Moein	6/27/01
·	A186	6,585,755	7/1/03	Jackson et al.	6/29/01
	A187	6,585,765	7/1/03	Hossainy et al.	6/29/00
	A188	6,585,926	7/1/03	Mirzaee	8/31/00
	A189	6,605,154	8/12/03	Villareal	5/31/01
	A190	6,623,448	9/23/03	Slater	3/30/01
	A191	6,625,486	9/23/03	Lundkvist et al.	4/11/01
	A192	6,645,135	11/11/03	Bhat	3/30/01
	A193	6,645,195	11/11/03	Bhat et al.	1/5/01
	A194	6,656,216	12/2/03	Hossainy et al.	6/29/01
	A195	6,656,506	12/2/03	Wu et al.	5/09/01
	A196	6,660,034	12/9/03	Mandrusov et al.	4/30/01
	A197	6,663,662	12/16/03	Pacetti et al.	12/28/00
	A198	6,666,880	12/23/03	Chiu et al.	6/19/01
	A199	6,673,154	1/6/04	Pacetti et al.	6/28/01
	A200	6,673,385	1/6/04	Ding et al.	6/28/01
	A201	6,689,099	2/10/04	Mirzaee	2/27/01
	A202	6,695,920	2/24/04	Pacetti et al.	6/27/01
	A203	6,706,013	3/16/04	Bhat et al.	6/29/01
	A204	6,712,845	3/30/04	Hossainy	4/24/01
	A205	6,713,119	3/30/04	Hossainy et al.	12/23/99
	A206	6,716,444	4/6/04	Castro et al.	9/28/00
	A207	6,740,040	5/25/04	Mandrusov et al.	1/30/01
	A208	6,743,462	6/1/04	Pacetti	5/31/01
	A209	6,749,626	6/15/04	. Bhat et al.	11/17/00
	A210	6,758,859	7/6/04	Dang et al.	10/30/00
	A211	6,759,054	7/6/04	Chen et al.	12/28/00

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation Yes No
	L T			ATENT DOCUMENTS		1	
-	A239	2002/0071822	6/13/02	Uhrich		<u> </u>	7/27/01
	A238	2002/0165608	11/7/02	Llanos et al.			6/22/01
	A237	2001/0037145	11/1/01	Guruwaiya et al.			6/21/01
	A236	2002/0183581	12/5/02	Yoe et al.			5/31/01
	A235	2002/0188277	12/12/02	Roorda et al.			5/18/01
	A234	2002/0032414	3/14/02	Ragheb et al.			5/7/01
	A233	2002/0016625	2/7/02	Falotico et al.			5/7/01
•	A232	2002/0007215	1/17/02	Falotico et al.			5/7/01
	A231	2002/0007214	1/17/02	Falotico			5/7/01
	A230	2002/0007213	1/17/02	Falotico et al.			5/7/01
	A229	2002/0005206	1/17/02	Falotico et al.			5/7/01
	A228	2001/0029351	10/11/01	Falotico et al.			5/7/01
	A227	2002/0155212	10/24/02	Hossainy			4/24/01
	A226	2002/0142039	10/3/02	Claude			3/30/01
	A225	2001/0020011	9/6/01	Mathiowitz et al.			3/23/01
	A224	2003/0032767	2/13/03	Tada et al.			2/5/01
	A223	2002/0087123	7/4/02	Hossainy et al.			1/2/01
	A222	2002/0123801	9/5/02	Pacetti et al.			12/28/00
	A221	2001/0018469	8/30/01	Chen et al.			12/28/00
	A220	2001/0014717	8/16/01	Hossainy et al.			12/28/00
	A219	2002/0120326	8/29/02	Michal			12/22/00
	A218	2002/0009604	1/24/02	Zamora et al.			12/21/00
	A217	2001/0007083	7/5/01	Roorda			12/21/00
.**!	A216	2002/0077693	6/20/02	Barclay et al.			12/19/00
	A215	2001/0051608	12/13/01	Mathiowitz et al.			10/15/98
xaminer Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date Appropriate
		U.S. PATE	NT APPLICAT	ION PUBLICATION DOCU	JMENTS		
	A214	6,899,731	5/31/05	Li et al.			1/2/01
	A213	6,887,485	5/3/05	Fitzhugh et al.			5/25/01
	A212	6,764,505	7/20/04	Hossainy et al.			4/12/01

	B1	2001-190687	7/17/01	Japan (English Abstract)			
	B2	DE 42 24 401	1/27/94	Germany			
	В3	EP 0 301 856	2/1/89	EPO			
	B4	EP 0 396 429	11/7/90	EPO			
	B5	EP 0 514 406	11/25/92	EPO			
	В6	EP 0 604 022	6/29/94	EPO			
	В7	EP 0 623 354	11/9/94	EPO			
	В8	EP 0 665 023	8/2/95	EPO			
	B9	EP 0 701 802	3/20/96	EPO			
	B10	EP 0 716 836	6/19/96	EPO			
	B11	EP 0 809 999	12/3/97	EPO			
	B12	EP 0 832 655	4/1/98	EPO		,	
	B13	EP 0 850 651	7/1/98	EPO			
	B14	EP 0 879 595	11/25/98	EPO			
	B15	EP 0 910 584	4/28/99	EPO	-		
	B16	EP 0 923 953	6/23/99	EPO			
	B17	EP 0 953 320	11/3/99	EPO			
	B18	EP 0 970 711	1/12/00	EPO			
	B19	EP 0 982 041	3/1/00	EPO	Wi		
	B20	EP 1 023 879	8/2/00	EPO			
	B21	EP 1 192 957	4/3/02	EPO			
	B22	EP 1 273 314	1/8/03	EPO			
	B23	SU 790725	2/9/83	SU (English Abstract)			
ì	B24	SU 811750	9/23/83	SU (English Abstract)			
	B25	SU 872531	10/15/81	SU (English Abstract)			
	B26	SU 876663	10/30/81	SU (English Abstract)			
	B27	SU 905228	2/15/82	SU (English Abstract)			
	B28	SU 1016314	5/7/83	` SU (English Abstract)			
	B29	SU 1293518	2/28/87	SU (English Abstract)			 _
	B30	WO 91/12846	9/5/91	PCT			
	B31	WO 94/09760	5/11/94	PCT			
	B32	WO 95/10989	4/27/95	PCT			

, Dan	WO 05/24000	0/04/05	PCT		
B33	WO 95/24929	9/21/95	PCT		
B34	WO 96/40174	12/19/96	1		
B35	WO 97/10011	3/20/97	PCT		
B36	WO 97/45105	12/4/97	PCT		<u> </u>
B37	WO 97/46590	12/11/97	PCT	-	
B38	WO 98/08463	3/5/98	PCT		
, B39	WO 98/17331	4/30/98	PCT	·	
B40	WO 98/32398	7/30/98	PCT		
B41	WO 98/36784	8/27/98	PCT		
B42	WO 99/01118	1/14/99	PCT		
B43	WO 99/38546	8/5/99	PCT		
B44	WO 99/63981	12/16/99	PCT		
B45	WO 00/02599	1/20/00	PCT		
B46	WO 00/12147	3/9/00	PCT		
B47	WO 00/18446	4/6/00	PCT		
B48	WO 00/64506	11/2/00	PCT		
B49	WO 01/01890	1/11/01	PCT		
B50	WO 01/15751	3/8/01	PCT		
B51	WO 01/17577	3/15/01	PCT		
B52	WO 01/45763	6/28/01	PCT		
B53	WO 01/49338	7/12/01	PCT		
B54	WO 01/51027	7/19/01	PCT	VIII THE	
B55	WO 01/74414	10/11/01	PCT		
B56	WO 02/003890	1/17/02	PCT		
B57	WO 02/026162	4/4/02	PCT		
B58	WO 02/034311	5/2/02	РСТ		
B59	WO 02/056790	7/25/02	PCT		
B60	WO 02/058753	8/1/02	РСТ		
B61	WO 02/102283	12/27/02	РСТ		
B62	WO 03/000308	1/3/03	PĊT		
B63	WO 03/022323	3/20/03	PCT		
B64	WO 03/028780	4/10/03	РСТ		

			T -	1	Τ -		
B65	WO 03/037223	5/8/03	PCT				
B66	WO 03/039612	5/15/03	PCT				
B67	WO 03/080147	10/2/03	PCT				
B68	WO 03/082368	10/9/03	PCT				
B69	WO 04/000383	12/31/03	PCT				
B70	WO 04/009145	1/29/04	PCT				
	OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertinent Pa	ages, etc.)			
C1	Anonymous, Cardiologists Draw - Up The Dream Stent, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959 , printed 8/25/03 (2 pages).						
C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), http://www.dialogweb.com/cgi/document?req=1061847871753, printed 8/25/03 (2 pages).						
C3	Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent (Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						
C4	Anonymous, Stenting continues to dominate cardiology, Clinica 720:22 (Sept. 2, 1996), http://www.dialogweb.com/cgi/document?reg=1061848017752, printed 8/25/03 (2 pages).						
C5	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).						
· C6	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).						
C7	Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).						
C8	Chung et al., Inner core segment design for drug delivery control of thermo-responsive polymeric micelles, Journal of Controlled Release 65:93-103 (2000).						
C9	Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).						
C10	Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).						
. C11							
. C12	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).						
C13	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).					diol.	
C14	Huang et al., Biodegradable Polymers Derived from Aminoacids, Macromol. Symp. 144, 7-32 (1999).						•
C15	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).						
C16	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).						
C17	Katsarava et al., Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarbolic Acids, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).						
C18	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).						

		,					
	C19	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).					
	C20	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).					
		Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).					
		Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).					
	C23	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).					
	C24	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , EPO Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).					
		Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).					
	C26	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).					
		Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).					
		Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).					
		Saotome, et al., Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid, Chemistry Letters, pp. 21-24, (1991).					
	C30	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).					
	C31	van Beusekom et al., <i>Coronary stent coatings</i> , Coronary Artery Disease 5(7):590-596 (July 1994).					
		Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).					
		Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).					
EXAMINER		DATE CONSIDERED					
EXAMINER: Ini	itial if refe	erences considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.					

SANFRANCISCO/162545.1

Include copy of this form with next communication to applicant.